Abstract

Yeast cell factories have emerged as versatile and robust platforms for the production of biopharmaceuticals, offering a scalable and customizable environment for therapeutic molecule synthesis. This abstract explores the transformative potential of customizing yeast cell factories in biopharmaceutical production, focusing on genetic engineering, pathway optimization, and therapeutic applications. By harnessing the genetic toolkit and metabolic capabilities of yeast, researchers can engineer high-yielding strains capable of producing a diverse array of therapeutic molecules, including proteins, peptides, antibodies, and vaccines. Moreover, yeast-based expression systems offer advantages such as post-translational modifications and scalability, making them attractive platforms for both research and industrial applications.